Details of the Drug

General Information of Drug (ID: DMX5SG7)

Drug Name
AZD1772//RDX5791
Indication
Disease Entry ICD 11 Status REF
Chronic kidney disease GB61 Phase 2 [1]
Cross-matching ID
TTD ID
D04AIB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/hydrogen exchanger 3 (SLC9A3) TTFZVPO SL9A3_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic kidney disease
ICD Disease Classification GB61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Sodium/hydrogen exchanger 3 (SLC9A3) DTT SLC9A3 6.83E-01 -0.03 -0.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of Ardelyx.
2 RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.